id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
7393795_3 | The induction of hypoglycaemia with PAS in this patient suggests a potential role for PAS in the treatment of diabetes mellitus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induction\"]], \"start\": [[4]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"hypoglycaemia\"]], \"start\": [[17]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"PAS\"]], \"start\": [[36]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"PAS\"]], \"start\": [[36]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"diabetes mellitus\"]], \"start\": [[110]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"this patient\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
8641617_1 | Although both patients recovered from the colitis after the administration of vancomycin, the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"recovered\"]], \"start\": [[23]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"vancomycin\"]], \"start\": [[78]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"colitis\"]], \"start\": [[42]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"vancomycin\"]], \"start\": [[78]], \"entity_id\": [\"T5\"]}}, \"Subject\": {\"text\": [[\"both patients\"]], \"start\": [[9]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"both\"]], \"start\": [[9]], \"entity_id\": [\"T10\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[149]], \"entity_id\": [\"T14\"]}, \"Effect\": {\"text\": [[\"a relapse of the colitis\"]], \"start\": [[118]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"a subsequent course of the same chemotherapy with cisplatin\"]], \"start\": [[159]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[209]], \"entity_id\": [\"T13\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[191]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15190230_1 | Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"therapy\"]], \"start\": [[49]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Acute dystonia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"pegylated interferon alpha\"]], \"start\": [[22]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"chronic hepatitis B infection\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"pegylated interferon alpha\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7696938_3 | I saw two patients with kala-azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion (in spite of tolerating a test dose). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[73]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"two patients with kala-azar resistant to sodium stibogluconate\"]], \"start\": [[6]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[6]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"resistant to sodium stibogluconate\"]], \"start\": [[34]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"cardiac arrest\"]], \"start\": [[83]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"amphotericin infusion\"]], \"start\": [[104]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"kala-azar\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"amphotericin\"]], \"start\": [[104]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[117]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
18515982_2 | CONCLUSIONS: Anastrozole may be the causative factor in patients with sclerosing glomerulonephritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causative\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Anastrozole\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Anastrozole\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[56]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"sclerosing glomerulonephritis\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[25]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
9399776_5 | We describe two cases of acute pancreatitis that occurred after long term mesalamine therapy for ulcerative colitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[25]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"mesalamine\"]], \"start\": [[74]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"ulcerative colitis\"]], \"start\": [[97]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"mesalamine\"]], \"start\": [[74]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
1673494_1 | Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"by\"]], \"start\": [[58]], \"entity_id\": [\"T18\"]}, \"Effect\": {\"text\": [[\"toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia\"]], \"start\": [[61]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"Amphotericin B (AmB)\"]], \"start\": [[0]], \"entity_id\": [\"T17\"], \"Drug\": {\"text\": [[\"Amphotericin B\"]], \"start\": [[0]], \"entity_id\": [\"T19\"]}}, \"Speculated\": {\"text\": [[\"common\"]], \"start\": [[135]], \"entity_id\": [\"T20\"], \"value\": true}}"
}
]
}
] |
1977935_6 | We believe that a drug interaction between terfenadine and ketoconazole resulted in the elevated terfenadine levels in plasma and in the cardiotoxicity previously seen only in cases of terfenadine overdose. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulted\"]], \"start\": [[72]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"a drug interaction between terfenadine and ketoconazole\"]], \"start\": [[16]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"terfenadine\"], [\"ketoconazole\"]], \"start\": [[43], [59]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[23]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"terfenadine\"], [\"ketoconazole\"]], \"start\": [[43], [59]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Effect\": {\"text\": [[\"the elevated terfenadine levels in plasma and in the cardiotoxicity\"]], \"start\": [[84]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
3405528_1 | A case of halothane induced hepatitis is reported in a middle aged woman who underwent gastric surgery for morbid obesity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a middle aged woman\"]], \"start\": [[53]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"middle aged\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"halothane\", \"gastric surgery for morbid obesity\"]], \"start\": [[10, 87]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"halothane\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"morbid obesity\"]], \"start\": [[107]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"hepatitis\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
448845_2 | Carbonic anhydrase inhibitors used in the treatment of glaucoma, seizure disorders, and hypertension are rarely associated with blood dyscrasias. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"rarely associated\"]], \"start\": [[105]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Carbonic anhydrase inhibitors\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Carbonic anhydrase inhibitors\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"glaucoma, seizure disorders, and hypertension\"]], \"start\": [[55]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"blood dyscrasias\"]], \"start\": [[128]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
282937_1 | Administration of intrathecal Ara-C in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild, transient neurological symptoms (paresthesias) in only one of 30 patients so treated. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulted\"]], \"start\": [[117]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Administration of intrathecal Ara-C in the same dose over longer intervals within 3-5 days between consecutive doses\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[18]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"Ara-C\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}, \"Freq\": {\"text\": [[\"longer intervals within 3-5 days between consecutive doses\"]], \"start\": [[58]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"neurological symptoms\"]], \"start\": [[145]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"one of 30 patients\"]], \"start\": [[190]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"one of 30\"]], \"start\": [[190]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"mild\"]], \"start\": [[129]], \"entity_id\": [\"T11\"], \"value\": \"Low\"}}"
}
]
}
] |
12751276_2 | Anaphylaxis from isoniazid is a possible side effect to this commonly prescribed antibiotic. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"is\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"isoniazid\", \"commonly prescribed antibiotic\"]], \"start\": [[17, 61]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"isoniazid\"]], \"start\": [[17]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Anaphylaxis\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"possible\"]], \"start\": [[32]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
9920368_2 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[133]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a patient with arrhythmogenic right ventricular dysplasia\"]], \"start\": [[30]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"amiodarone for 4 years\"]], \"start\": [[109]], \"entity_id\": [\"T8\"], \"Duration\": {\"text\": [[\"4 years\"]], \"start\": [[124]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[109]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"arrhythmogenic right ventricular dysplasia\"]], \"start\": [[45]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII)\"]], \"start\": [[143]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
18094347_5 | Methotrexate-induced papular eruption following treatment of psoriasis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"psoriasis\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"papular eruption\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18533420_3 | Sexual dysfunction associated with intrathecal baclofen use: a report of two cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Sexual dysfunction\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intrathecal baclofen\"]], \"start\": [[35]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[35]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"baclofen\"]], \"start\": [[47]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[73]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[73]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11030530_2 | Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"present\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"Patients\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[22]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hemorrhagic and thrombotic cerebrovascular events\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[37]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
15611427_3 | Since imiquimod induces large amounts of type I interferon production from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induces\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"imiquimod\"]], \"start\": [[6]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"imiquimod\"]], \"start\": [[6]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"large amounts of type I interferon production\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16405935_2 | Ptosis occurring 24 h after chloroquine therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[7]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Ptosis\"], [\"full recovery 48 h after cessation of chloroquine\"]], \"start\": [[0], [54]], \"entity_id\": [\"T4\", \"T9\"]}, \"Treatment\": {\"text\": [[\"chloroquine therapy\"]], \"start\": [[28]], \"entity_id\": [\"T6\"], \"Time_elapsed\": {\"text\": [[\"24 h\"]], \"start\": [[17]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"chloroquine\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"full recovery\"]], \"start\": [[54]], \"entity_id\": [\"T10\"], \"value\": \"Low\"}}"
}
]
}
] |
17494808_1 | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[43]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Hypersensitivity pneumonitis-like syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lenalidomide\"]], \"start\": [[70]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"lenalidomide\"]], \"start\": [[70]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11033734_2 | Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"pediatric cancer patients\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[25]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"cancer\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"imipenem/cilastatin\"]], \"start\": [[64]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"imipenem\"], [\"cilastatin\"]], \"start\": [[64], [73]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[72]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"imipenem\"], [\"cilastatin\"]], \"start\": [[64], [73]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
6260900_2 | One of these was clofazimine, an aniline aposafranine derivative known to produce a ceroid-like pigment in the tissues of patients treated with this drug or lepromatous leprosy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"produce\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"clofazimine\"]], \"start\": [[17]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"lepromatous leprosy\"]], \"start\": [[157]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"clofazimine\"]], \"start\": [[17]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"a ceroid-like pigment\"]], \"start\": [[82]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"patients treated with this drug or lepromatous leprosy\"]], \"start\": [[122]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
331881_1 | Deposits of plasma proteins in the skin during treatment with carbamazepine and diphenylhydantoin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"carbamazepine and diphenylhydantoin\"]], \"start\": [[62]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"carbamazepine\"], [\"diphenylhydantoin\"]], \"start\": [[62], [80]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"carbamazepine\"], [\"diphenylhydantoin\"]], \"start\": [[62], [80]], \"entity_id\": [\"T8\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"Deposits of plasma proteins in the skin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
14690166_1 | 2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"accelerate\"]], \"start\": [[90]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"2-Chloro-deoxyadenosine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"2-Chloro-deoxyadenosine\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"Castleman's disease\"]], \"start\": [[62]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"non-Hodgkin's lymphoma\"]], \"start\": [[123]], \"entity_id\": [\"T11\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[86]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
10393393_1 | Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"manifested\"]], \"start\": [[35]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"aspirin\"]], \"start\": [[20]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"aspirin\"]], \"start\": [[20]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"acute asthma\", \"urticaria\", \"angioedema\", \"systemic anaphylactoid reaction\"], [\"Hypersensitivity\"]], \"start\": [[49, 63, 80, 97], [0]], \"entity_id\": [\"T9\", \"T10\"]}, \"Speculated\": {\"text\": [[\"can\"]], \"start\": [[28]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
19224802_1 | An exaggerated hypertensive response to glycopyrrolate therapy for bradycardia associated with high-dose dexmedetomidine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[79]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"bradycardia\"]], \"start\": [[67]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"high-dose dexmedetomidine\"]], \"start\": [[95]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"dexmedetomidine\"]], \"start\": [[105]], \"entity_id\": [\"T12\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[95]], \"entity_id\": [\"T16\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"response\"]], \"start\": [[28]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"glycopyrrolate\"]], \"start\": [[40]], \"entity_id\": [\"T14\"], \"Disorder\": {\"text\": [[\"bradycardia\"]], \"start\": [[67]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"glycopyrrolate\"]], \"start\": [[40]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"exaggerated hypertensive\"]], \"start\": [[3]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
8530331_7 | Only one patient, the youngest, did well on risperidone therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"did well\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"the youngest\"]], \"start\": [[18]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"risperidone\"]], \"start\": [[44]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"risperidone\"]], \"start\": [[44]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7019786_3 | Two elderly women suffered an acute deterioration of renal function after treatment with cefoxitin sodium. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[68]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"Two elderly women\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[4]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"acute deterioration of renal function\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"treatment with cefoxitin sodium\"]], \"start\": [[74]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cefoxitin sodium\"]], \"start\": [[89]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
19904536_14 | Physicians should suspect pulmonary toxicity in patients with respiratory distress after gemcitabine chemotherapy, mainly in elderly patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[83]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"pulmonary toxicity\"]], \"start\": [[26]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"patients with respiratory distress\", \"mainly in elderly patients\"]], \"start\": [[48, 115]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"gemcitabine chemotherapy\"]], \"start\": [[89]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"gemcitabin\"]], \"start\": [[89]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"respiratory distress\"]], \"start\": [[62]], \"entity_id\": [\"T14\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[101]], \"entity_id\": [\"T16\"]}}, \"Speculated\": {\"text\": [[\"suspect\"]], \"start\": [[18]], \"entity_id\": [\"T15\"], \"value\": true}}"
}
]
}
] |
9022114_3 | Delay of corneal wound healing in patients treated with colchicine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[34]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"colchicine\"]], \"start\": [[56]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"colchicine\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Delay of corneal wound healing\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9920368_1 | Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Amiodarone\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Amiodarone\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"thyrotoxicosis\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
18721173_1 | CONCLUSION: All doctors need to be aware of the need to review the indications for gabapentin use during periods of acute illness, especially with regard to renal impairment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"regard\"]], \"start\": [[147]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"gabapentin\"]], \"start\": [[83]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"acute illness\"]], \"start\": [[116]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"gabapentin\"]], \"start\": [[83]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"renal impairment\"]], \"start\": [[157]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
21751692_4 | EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"observed\"]], \"start\": [[14]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"all 7 patients\"]], \"start\": [[26]], \"entity_id\": [\"T11\"], \"Population\": {\"text\": [[\"7\"]], \"start\": [[30]], \"entity_id\": [\"T15\"]}}, \"Treatment\": {\"text\": [[\"propofol TIVA\"], [\"low-dose ketamine was added to propofol\"]], \"start\": [[61], [152]], \"entity_id\": [\"T12\", \"T17\"], \"Drug\": {\"text\": [[\"propofol\"], [\"ketamine\"], [\"propofol\"]], \"start\": [[61], [161], [183]], \"entity_id\": [\"T16\", \"T19\", \"T20\"]}, \"Route\": {\"text\": [[\"TIVA\"]], \"start\": [[70]], \"entity_id\": [\"T22\"]}, \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[152]], \"entity_id\": [\"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"added\"]], \"start\": [[174]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"propofol\"], [\"ketamine\"]], \"start\": [[183], [161]], \"entity_id\": [\"T20\", \"T19\"]}}]}, \"Effect\": {\"text\": [[\"EA signs\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
9788533_8 | The cause of death was multiple drug intoxication following acute use of sertraline, the manner of death was suicide, and the mechanism of death is an unexplained drug interaction and/or toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[50]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"multiple drug intoxication\"]], \"start\": [[23]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"sertraline\"]], \"start\": [[73]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"sertraline\"]], \"start\": [[73]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"unexplained\"]], \"start\": [[151]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
9362107_2 | On the next day, after a total dose of only 600 mg of danazol, gingival bleeding and purpura occurred. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[93]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"gingival bleeding and purpura\"]], \"start\": [[63]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"On the next day, after a total dose of only 600 mg of danazol\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"a total dose of only 600 mg\"]], \"start\": [[23]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
1393348_4 | SLE receded after withdrawal of carbamazepine and treatment with anti-inflammatory drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"withdrawal of carbamazepine and treatment with anti-inflammatory drugs\"]], \"start\": [[18]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"carbamazepine\"], [\"anti-inflammatory\"]], \"start\": [[32], [65]], \"entity_id\": [\"T6\", \"T7\"]}, \"Disorder\": {\"text\": [[\"SLE\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8828999_1 | a 67-year-old man with bipolar disorder developed a Creutzfeldt-Jakob like syndrome during lithium carbonate treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[84]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a 67-year-old man with bipolar disorder\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"67-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Creutzfeldt-Jakob like syndrome\"]], \"start\": [[52]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"lithium carbonate\"]], \"start\": [[91]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"lithium carbonate\"]], \"start\": [[91]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"bipolar disorder\"]], \"start\": [[23]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
7679525_2 | A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included bleomycin, developed life threatening interstitial pneumonitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[107]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"42 year old man\"]], \"start\": [[2]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"42 year old\"]], \"start\": [[2]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}}, \"Treatment\": {\"text\": [[\"combination chemotherapy that included bleomycin,\"]], \"start\": [[57]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"testicular carcinoma\"]], \"start\": [[31]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"bleomycin\"]], \"start\": [[96]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"interstitial pneumonitis\"]], \"start\": [[134]], \"entity_id\": [\"T9\"]}, \"Severity\": {\"text\": [[\"life threatening\"]], \"start\": [[117]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
}
]
}
] |
18446030_1 | Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[78]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"efalizumab therapy\"]], \"start\": [[85]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"psoriasis\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"efalizumab\"]], \"start\": [[85]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"an adult psoriasis patient\"]], \"start\": [[51]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"adult\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Disseminated eruptive giant mollusca contagiosa\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
812008_2 | Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"improvement\"]], \"start\": [[21]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"withdrawal of the diphenylhydantoin\"]], \"start\": [[59]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"porphyria\"]], \"start\": [[40]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"diphenylhydantoin\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
18294121_5 | Temozolomide was restarted 2 months later; the patient again developed a fever. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[61]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"fever\"]], \"start\": [[73]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Temozolomide\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Temozolomide\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9337441_16 | The patient's previous rash and the temporal relation of this event and the ingestion of phenolphthalein, as well as the similarity of this case to other reports, point to phenolphthalein as the cause of TEN in this patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[195]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ingestion of phenolphthalein\"]], \"start\": [[76]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"phenolphthalein\"]], \"start\": [[89]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[76]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"TEN\"]], \"start\": [[204]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"The patient's previous rash\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"rash\"]], \"start\": [[23]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
15592331_12 | Ciprofloxacin greatly elevates plasma concentrations of tizanidine and dangerously potentiates its hypotensive and sedative effects, mainly by inhibiting its CYP1A2-mediated metabolism, at least when administered 1 hour before tizanidine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"elevates\"]], \"start\": [[22]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"Ciprofloxacin\"], [\"tizanidine\"], [\"tizanidine\"]], \"start\": [[0], [56], [227]], \"entity_id\": [\"T13\", \"T14\", \"T15\"]}}, \"Effect\": {\"text\": [[\"plasma concentrations of tizanidine and dangerously potentiates its hypotensive and sedative effects\"]], \"start\": [[31]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
11328247_4 | RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an increased libido with the administration of fluvoxamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[97]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"The patient, a 27-year-old married Japanese woman with borderline personality disorder\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"27-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}, \"Race\": {\"text\": [[\"Japanese\"]], \"start\": [[44]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[53]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"increased libido\"]], \"start\": [[110]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"administration of fluvoxamine\"]], \"start\": [[136]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"borderline personality disorder\"]], \"start\": [[64]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[154]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
9403220_2 | Acute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[59]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"enalapril\"]], \"start\": [[124]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"enalapril\"]], \"start\": [[124]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"minimal change nephrotic syndrome\"]], \"start\": [[77]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"a patient with minimal change nephrotic syndrome\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Acute renal failure with severe tubulointerstitial changes\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[25]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
19667003_2 | PURPOSE: A case of carbamazepine-induced hyperammonemia is presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A case\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\"]], \"start\": [[19]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[19]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hyperammonemia\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
7919557_4 | The cough continued for the duration of therapy with quinapril. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"continued\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"cough\"]], \"start\": [[4]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"quinapril\"]], \"start\": [[53]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"quinapril\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
15685264_2 | OBJECTIVE: To report a case of Carbamazepine toxicity following the administration of Oxybutynin and Dantrolene. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Carbamazepine\", \"Oxybutynin and Dantrolene\"]], \"start\": [[31, 86]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"Oxybutynin\"], [\"Dantrolene\"], [\"Carbamazepine\"]], \"start\": [[86], [101], [31]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"administration\"]], \"start\": [[68]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"Carbamazepine\"], [\"Oxybutynin\"], [\"Dantrolene\"]], \"start\": [[31], [86], [101]], \"entity_id\": [\"T13\", \"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"Carbamazepine toxicity\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
9362107_1 | Danazol induced thrombocytopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[8]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Danazol\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Danazol\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia\"]], \"start\": [[16]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16005413_5 | Four elderly LTCF residents treated with serotonergic antidepressants including selective serotonin reuptake inhibitor (SSRI) or mirtazapine and opioids. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[28]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"Four elderly LTCF residents\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"Four\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[5]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"serotonergic antidepressants including selective serotonin reuptake inhibitor (SSRI) or mirtazapine and opioids\"]], \"start\": [[41]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"LTCF\"]], \"start\": [[13]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"selective serotonin reuptake inhibitor\"], [\"mirtazapine\"], [\"opioids\"]], \"start\": [[80], [129], [145]], \"entity_id\": [\"T16\", \"T17\", \"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[141]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"opioids\"], [\"mirtazapine\"]], \"start\": [[145], [129]], \"entity_id\": [\"T18\", \"T17\"]}}]}}"
}
]
}
] |
1772299_1 | Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[54]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"eosinophilia-myalgia syndrome\"]], \"start\": [[88]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"L-tryptophan\"]], \"start\": [[67]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"L-tryptophan\"]], \"start\": [[67]], \"entity_id\": [\"T4\"]}}}"
}
]
}
] |
8942269_2 | His impaired memory was found to be due to the atenolol he was on and he made a complete recovery on withdrawing the beta-blocker. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[36]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"impaired memory\"]], \"start\": [[4]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[56]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"he\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"atenolol\"]], \"start\": [[47]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"atenolol\"]], \"start\": [[47]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15388215_1 | Tiagabine overdose causes an unusual array of neurological symptoms, many similar to reported adverse effects during therapeutic use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Tiagabine overdose\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Tiagabine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"an unusual array of neurological symptoms\"]], \"start\": [[26]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8496127_2 | This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[111]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"6.9-year-old autistic male\"]], \"start\": [[24]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"6.9-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"autistic\"]], \"start\": [[37]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[46]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"repeated episodes of acute dystonic reactions\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration\"]], \"start\": [[127]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"pimozide\"], [\"pimozide\"], [\"thioridazine\"]], \"start\": [[127], [226], [276]], \"entity_id\": [\"T12\", \"T17\", \"T18\"]}, \"Dosage\": {\"text\": [[\"0.096 mg/kg\"], [\"0.032 mg/kg\"]], \"start\": [[167], [187]], \"entity_id\": [\"T13\", \"T15\"]}, \"Freq\": {\"text\": [[\"day\"], [\"day\"]], \"start\": [[179], [199]], \"entity_id\": [\"T14\", \"T16\"]}}}"
}
]
}
] |
9169264_1 | Cephalexin rash in infectious mononucleosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Cephalexin rash\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Cephalexin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Cephalexin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"infectious mononucleosis\"]], \"start\": [[19]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19122478_6 | He developed recurrent skin rash, fever, hypereosinophilia, and acute renal failure after rechallenge with chlorambucil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[3]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"recurrent skin rash, fever, hypereosinophilia, and acute renal failure\"]], \"start\": [[13]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"rechallenge with chlorambucil\"]], \"start\": [[90]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"chlorambucil\"]], \"start\": [[107]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
464813_1 | Lower extremity arterial insufficiency after long-term methysergide maleate therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Lower extremity arterial insufficiency\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"long-term methysergide maleate therapy\"]], \"start\": [[45]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methysergide maleate\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}, \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11788010_3 | Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hepatolithiasis (intrahepatic stone)\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"octreotide\"]], \"start\": [[44]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"octreotide\"]], \"start\": [[44]], \"entity_id\": [\"T5\"]}, \"Disorder\": {\"text\": [[\"acromegaly\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
16527771_1 | Acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[35]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute unilateral total visual loss\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"retrogasserian phenol injection\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"injection\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"retrogasserian phenol\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"trigeminal neuralgia\"]], \"start\": [[94]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19995222_4 | OBJECTIVE: Clozapine causes few extrapyramidal symptoms and is recommended as a treatment drug for severe tardive dyskinesia (TD). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Clozapine\"]], \"start\": [[11]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Clozapine\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"few extrapyramidal symptoms\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
22791547_1 | Methylphenidate-induced acute orofacial and extremity dyskinesia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[16]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Methylphenidate\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Methylphenidate\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"acute orofacial and extremity dyskinesia\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7946029_1 | Basilar invagination and mid-line skeletal abnormalities due to in utero exposure to phenytoin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Basilar invagination and mid-line skeletal abnormalities\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"utero exposure to phenytoin\"]], \"start\": [[67]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[85]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
18682542_2 | DISCUSSION: To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin/tazobactam. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"triggered\"]], \"start\": [[94]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"neuralgic amyotrophy\"]], \"start\": [[73]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"antibiotics vancomycin, tobramycin, and piperacillin/tazobactam\"]], \"start\": [[123]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"vancomycin\"], [\"tobramycin\"], [\"piperacillin\"], [\"tazobactam\"]], \"start\": [[135], [147], [163], [176]], \"entity_id\": [\"T9\", \"T10\", \"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[159]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"vancomycin\"], [\"tobramycin\"], [\"piperacillin\"], [\"tazobactam\"]], \"start\": [[135], [147], [163], [176]], \"entity_id\": [\"T9\", \"T10\", \"T11\", \"T12\"]}}]}}"
}
]
}
] |
9840249_1 | Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[34]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Alveolar-interstitial pneumopathy\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"gold-salts compounds administration\"]], \"start\": [[40]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"gold-salts compounds\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
15373932_10 | This study revealed that ketoconazole affected the disposition of rosiglitazone in humans, probably by the inhibition of CYP2C8 and CYP2C9, leading to increasing rosiglitazone concentrations that could increase the efficacy of rosiglitazone or its adverse events. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"leading to\"]], \"start\": [[140]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"increasing rosiglitazone concentrations that could increase the efficacy of rosiglitazone or its adverse events\"]], \"start\": [[151]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"ketoconazole\"]], \"start\": [[25]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"ketoconazole\"]], \"start\": [[25]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"humans\"]], \"start\": [[83]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
25538343_4 | We report a case of duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"duloxetine\", \"thiazide diuretics\"]], \"start\": [[20, 87]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"duloxetine\"], [\"thiazide diuretics\"]], \"start\": [[20], [87]], \"entity_id\": [\"T12\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"treated with\"]], \"start\": [[74]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"thiazide diuretics\"], [\"duloxetine\"]], \"start\": [[87], [20]], \"entity_id\": [\"T14\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"hyponatremia\"]], \"start\": [[39]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"an elderly patient\"]], \"start\": [[55]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[58]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
3892171_1 | Protamine-induced fatal anaphylaxis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Protamine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Protamine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"anaphylaxis\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[18]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
9362107_3 | We diagnosed this case as danazol induced thrombocytopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"danazol\"]], \"start\": [[26]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"this case\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8530331_5 | One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[131]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"One patient\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"One\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"risperidone\"]], \"start\": [[119]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"risperidone\"]], \"start\": [[119]], \"entity_id\": [\"T13\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[203]], \"entity_id\": [\"T17\"]}, \"Subject\": {\"text\": [[\"One patient\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"One\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"was able to return home and have the gastrostomy removed\"]], \"start\": [[146]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"switching from risperidone to clozapine\"]], \"start\": [[209]], \"entity_id\": [\"T18\"], \"Disorder\": {\"text\": [[\"worsening parkinsonism\"]], \"start\": [[89]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"risperidone\"], [\"clozapine\"]], \"start\": [[224], [239]], \"entity_id\": [\"T19\", \"T20\"]}}}"
}
]
}
] |
9776099_1 | NMS is a drug-related response to various medications, such as Haloperidol, which the patient was receiving. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"response\"]], \"start\": [[22]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Haloperidol\"]], \"start\": [[63]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Haloperidol\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[86]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"NMS\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15770343_3 | In addition, ethambutol rarely causes visual loss during the early period or when given at lower doses. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ethambutol\", \"during the early period or when given at lower doses\"]], \"start\": [[13, 50]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"early period\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"lower doses\"]], \"start\": [[91]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"visual loss\"]], \"start\": [[38]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11215836_4 | The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"stopped\"]], \"start\": [[28]], \"entity_id\": [\"T19\"]}, \"Effect\": {\"text\": [[\"behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused\"]], \"start\": [[98]], \"entity_id\": [\"T20\"]}, \"Treatment\": {\"text\": [[\"day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d\"]], \"start\": [[4]], \"entity_id\": [\"T21\"], \"Drug\": {\"text\": [[\"clozapine\"], [\"clomipramine\"]], \"start\": [[14], [66]], \"entity_id\": [\"T24\", \"T25\"]}, \"Dosage\": {\"text\": [[\"150 mg/d\"]], \"start\": [[79]], \"entity_id\": [\"T26\"]}}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[89]], \"entity_id\": [\"T22\"], \"Gender\": {\"text\": [[\"he\"]], \"start\": [[89]], \"entity_id\": [\"T23\"]}}}"
}
]
}
] |
9494448_4 | CONCLUSIONS: Hypersensitivity reactions to cyclosporine are due to Cremophor EL. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hypersensitivity reactions to cyclosporine\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Cremophor EL\"]], \"start\": [[67]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Cremophor EL\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10656221_2 | There are few reports in the literature related to sulfonylurea-induced hepatotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[64]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"sulfonylurea\"]], \"start\": [[51]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"sulfonylurea\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17406804_4 | Radiation recall pneumonitis induced by gemcitabine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Radiation recall pneumonitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"gemcitabine\"]], \"start\": [[40]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8266863_1 | Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[85]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"injection of 3.6 mg of goserelin acetate\"]], \"start\": [[28]], \"entity_id\": [\"T7\"], \"Route\": {\"text\": [[\"injection\"]], \"start\": [[28]], \"entity_id\": [\"T13\"]}, \"Dosage\": {\"text\": [[\"3.6 mg\"]], \"start\": [[41]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"goserelin acetate\"]], \"start\": [[51]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"severe dyspnea\"], [\"worsening pleuritis carcinomatosa\"]], \"start\": [[70], [102]], \"entity_id\": [\"T8\", \"T10\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[70]], \"entity_id\": [\"T11\"], \"value\": \"Medium\"}, \"Speculated\": {\"text\": [[\"considered\"]], \"start\": [[147]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
11675845_4 | Ropinirole was added to his current therapy for Parkinson disease, with a corresponding decrease in the dose of levodopa/carbidopa to allow levodopa sparing. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"added\"]], \"start\": [[15]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Ropinirole\", \"a corresponding decrease in the dose of levodopa/carbidopa to allow levodopa sparing\"]], \"start\": [[0, 72]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Ropinirole\"], [\"levodopa\"], [\"carbidopa\"]], \"start\": [[0], [112], [121]], \"entity_id\": [\"T10\", \"T12\", \"T13\"]}, \"Disorder\": {\"text\": [[\"Parkinson disease\"]], \"start\": [[48]], \"entity_id\": [\"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[67]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"Ropinirole\"], [\"levodopa\"], [\"carbidopa\"]], \"start\": [[0], [112], [121]], \"entity_id\": [\"T10\", \"T12\", \"T13\"]}}]}}"
}
]
}
] |
11703329_2 | Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent severe neurotoxicity of polychemotherapy by avoiding vincristine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"by\"]], \"start\": [[129]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"severe neurotoxicity of polychemotherapy\"]], \"start\": [[88]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"vincristine\"]], \"start\": [[141]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"HMSN\"]], \"start\": [[27]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"vincristine\"]], \"start\": [[141]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[88]], \"entity_id\": [\"T7\"], \"value\": \"Medium\"}}"
}
]
}
] |
17285101_3 | This is the first report of pulmonary hypertension in an adult patient during lithium therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[71]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"an adult patient\"]], \"start\": [[54]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"adult\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"lithium therapy.\"]], \"start\": [[78]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[78]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"pulmonary hypertension\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15307435_2 | In this report, we present a case of hypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"hypoglycaemic coma\", \"an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases\"]], \"start\": [[37, 76]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"SP\"]], \"start\": [[72]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"SP\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7439122_2 | However, we have recently had four cases of clofibrate-induced myopathy in patients with diabetes insipidus due to hypothalamic lesions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"four cases\", \"diabetes insipidus due to hypothalamic lesions\"]], \"start\": [[30, 89]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"clofibrate\"]], \"start\": [[44]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"clofibrate\"]], \"start\": [[44]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"diabetes insipidus\"]], \"start\": [[89]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"myopathy\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9052919_2 | One patient had MRI T2 abnormalities compatible with cyclosporin neurotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"One patient\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"One\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"cyclosporin\"]], \"start\": [[53]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cyclosporin\"]], \"start\": [[53]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"neurotoxicity\", \"MRI T2 abnormalities\"]], \"start\": [[65, 16]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
21751666_1 | Post-exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient--safe and effective without any immunosuppresive drug interaction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"Post-exposure prophylaxis\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"oseltamivir\"]], \"start\": [[40]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"H1N1\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"oseltamivir\"]], \"start\": [[40]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"renal allograft recipient\"]], \"start\": [[55]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"renal allograft\"]], \"start\": [[55]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"safe and effective without any immunosuppresive drug interaction\"]], \"start\": [[82]], \"entity_id\": [\"T1\"]}}"
}
]
}
] |
8140860_3 | Seven days after the introduction of amoxycillin (500 mg/8 h) for a probable respiratory infection, the patient developed spontaneous bruising, with an INR of 7.1. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[112]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Seven days after the introduction of amoxycillin (500 mg/8 h)\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"a probable respiratory infection\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}, \"Time_elapsed\": {\"text\": [[\"Seven days after\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"amoxycillin\"]], \"start\": [[37]], \"entity_id\": [\"T12\"]}, \"Dosage\": {\"text\": [[\"500 mg/8 h\"]], \"start\": [[50]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[100]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"spontaneous bruising, with an INR of 7.1\"]], \"start\": [[122]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
15383642_2 | To report a case in which significant hypotension occurred after initiation of tizanidine in a patient using the antihypertensive agent lisinopril. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[59]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"hypotension\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"initiation of tizanidine\", \"lisinopril\"]], \"start\": [[65, 136]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"lisinopril\"], [\"tizanidine\"]], \"start\": [[136], [79]], \"entity_id\": [\"T12\", \"T13\"]}}, \"Subject\": {\"text\": [[\"a patient\"], [\"a case\"]], \"start\": [[93], [10]], \"entity_id\": [\"T11\", \"T14\"]}}"
}
]
}
] |
23624139_3 | We herein describe a case of severe hyponatremia complicated by seizure and coma due to the intake of non-steroidal anti-inflammatory drugs (NSAIDs) in a patient on DDAVP replacement therapy for central diabetes insipidus (DI). | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[81]], \"entity_id\": [\"T16\"]}, \"Effect\": {\"text\": [[\"severe hyponatremia\"], [\"seizure and coma\"]], \"start\": [[29], [64]], \"entity_id\": [\"T12\", \"T17\"]}, \"Treatment\": {\"text\": [[\"intake of non-steroidal anti-inflammatory drugs (NSAIDs)\", \"on DDAVP replacement therapy\"]], \"start\": [[92, 162]], \"entity_id\": [\"T15\"], \"Drug\": {\"text\": [[\"non-steroidal anti-inflammatory drugs\"], [\"DDAVP\"]], \"start\": [[102], [165]], \"entity_id\": [\"T19\", \"T20\"]}, \"Disorder\": {\"text\": [[\"central diabetes insipidus\"]], \"start\": [[195]], \"entity_id\": [\"T22\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"on\"]], \"start\": [[162]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"DDAVP\"], [\"non-steroidal anti-inflammatory drugs\"]], \"start\": [[165], [102]], \"entity_id\": [\"T20\", \"T19\"]}}]}, \"Subject\": {\"text\": [[\"a patient\", \"for central diabetes insipidus (DI)\"]], \"start\": [[152, 191]], \"entity_id\": [\"T13\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[29]], \"entity_id\": [\"T18\"], \"value\": \"Medium\"}}"
}
]
}
] |
11213850_6 | Each subject was treated according to the following sequence: baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52). | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[17]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"Each subject\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52)\"]], \"start\": [[62]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"cisapride\"], [\"fluoxetine\"], [\"cisapride\"], [\"fluoxetine\"]], \"start\": [[92], [164], [212], [258]], \"entity_id\": [\"T11\", \"T14\", \"T16\", \"T19\"]}, \"Dosage\": {\"text\": [[\"10 mg\"], [\"20 mg/day\"], [\"10 mg\"], [\"20 mg/day\"]], \"start\": [[102], [175], [222], [269]], \"entity_id\": [\"T12\", \"T15\", \"T17\", \"T20\"]}, \"Freq\": {\"text\": [[\"4 times/day\"], [\"4 times/day\"]], \"start\": [[108], [228]], \"entity_id\": [\"T13\", \"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"plus\"]], \"start\": [[253]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"cisapride\"], [\"fluoxetine\"]], \"start\": [[212], [258]], \"entity_id\": [\"T16\", \"T19\"]}}]}}"
}
]
}
] |
412488_7 | These findings are consistent with an immune-complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[304]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"gold therapy in rheumatoid arthritis\"]], \"start\": [[320]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"gold\"]], \"start\": [[320]], \"entity_id\": [\"T17\"]}, \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[336]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"renal disease\"]], \"start\": [[290]], \"entity_id\": [\"T18\"]}, \"Speculated\": {\"text\": [[\"may be\"]], \"start\": [[257]], \"entity_id\": [\"T15\"], \"value\": true}}"
}
]
}
] |
7304798_1 | Induction of rapid mood cycling during L-dopa treatment in a bipolar patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[32]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"rapid mood cycling\"]], \"start\": [[13]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"L-dopa\"]], \"start\": [[39]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"L-dopa\"]], \"start\": [[39]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"bipolar\"]], \"start\": [[61]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"a bipolar patient\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
11144696_2 | To report a patient having a first-time seizure after receiving venlafaxine and trimipramine for depression. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"venlafaxine and trimipramine\"]], \"start\": [[64]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"venlafaxine\"], [\"trimipramine\"]], \"start\": [[64], [80]], \"entity_id\": [\"T12\", \"T13\"]}, \"Disorder\": {\"text\": [[\"depression\"]], \"start\": [[97]], \"entity_id\": [\"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[76]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"venlafaxine\"], [\"trimipramine\"]], \"start\": [[64], [80]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Effect\": {\"text\": [[\"seizure\"]], \"start\": [[40]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
282937_3 | Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Paraplegia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"prophylactic intrathecal cytosine arabinoside (Ara-C)\", \"doses of 100 mg/m2/d for 5 consecutive days\"]], \"start\": [[21, 159]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[46]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[34]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"acute myelogenous leukemia in remission\"]], \"start\": [[106]], \"entity_id\": [\"T11\"]}, \"Dosage\": {\"text\": [[\"100 mg/m2/d\"]], \"start\": [[168]], \"entity_id\": [\"T12\"]}, \"Duration\": {\"text\": [[\"5 consecutive days\"]], \"start\": [[184]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"a patient with acute myelogenous leukemia in remission\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
19402273_2 | Isoniazid induced gynaecomastia: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Isoniazid\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Isoniazid\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"gynaecomastia\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17671884_7 | One previous study of four transplant patients whose immediate post-transplantation immunosuppression utilized corticosteroids, cyclosporine, MMF, and anti-T-lymphocyte globulin noted anemia in 13% of them. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"noted\"]], \"start\": [[178]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"anemia\"]], \"start\": [[184]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"four transplant patients\"]], \"start\": [[22]], \"entity_id\": [\"T12\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[22]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"transplant\"]], \"start\": [[27]], \"entity_id\": [\"T15\"]}}, \"Treatment\": {\"text\": [[\"immediate post-transplantation immunosuppression utilized corticosteroids, cyclosporine, MMF, and anti-T-lymphocyte globulin\"]], \"start\": [[53]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"corticosteroids\"], [\"cyclosporine\"], [\"MMF\"], [\"anti-T-lymphocyte globulin\"]], \"start\": [[111], [128], [142], [151]], \"entity_id\": [\"T16\", \"T17\", \"T18\", \"T19\"]}, \"Disorder\": {\"text\": [[\"post-transplantation immunosuppression\"]], \"start\": [[63]], \"entity_id\": [\"T1\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[147]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"cyclosporine\"], [\"MMF\"], [\"anti-T-lymphocyte globulin\"]], \"start\": [[111], [128], [142], [151]], \"entity_id\": [\"T16\", \"T17\", \"T18\", \"T19\"]}}]}}"
}
]
}
] |
1348483_2 | Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"cabergoline\"]], \"start\": [[101]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"Parkinson's disease\"]], \"start\": [[44]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"cabergoline\"]], \"start\": [[101]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Pleuropulmonary changes\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
3982906_2 | However, each infant demonstrated hemodynamic decompensation shortly after verapamil administration and required cardiopulmonary resuscitation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"demonstrated\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"each infant\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hemodynamic decompensation\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"verapamil\"]], \"start\": [[75]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"verapamil\"]], \"start\": [[75]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11160777_11 | Long-term studies are needed to determine whether the insulin-sensitizing effects of the glitazones can prevent or delay premature atherosclerotic cardiovascular disease, morbidity, and death. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prevent\"]], \"start\": [[104]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"glitazones\"]], \"start\": [[89]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"premature atherosclerotic cardiovascular disease, morbidity, and death\"]], \"start\": [[121]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"glitazones\"]], \"start\": [[89]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
7663030_1 | Probable propafenone-induced transient global amnesia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"propafenone\"]], \"start\": [[9]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"propafenone\"]], \"start\": [[9]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"transient global amnesia\"]], \"start\": [[29]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
16119501_3 | The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"have\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"24 hours of reinstitution of full preadmission dosing of oral baclofen\"]], \"start\": [[123]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"oral\"]], \"start\": [[180]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"baclofen\"]], \"start\": [[185]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"24 hours\"]], \"start\": [[123]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"fever and autonomic instability without evidence of infection which entirely resolved\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16629074_2 | Traumatic late flap dehiscence and Enterobacter keratitis following LASIK. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"LASIK\"]], \"start\": [[68]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"LASIK\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Traumatic late flap dehiscence and Enterobacter keratitis\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
2305654_2 | We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of adynamic ileus, while being treated with intravenous nimodipine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"patient with subarachnoid haemorrhage\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"pseudo-obstruction of the colon\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"intravenous nimodipine\"]], \"start\": [[180]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"subarachnoid haemorrhage\"]], \"start\": [[28]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"nimodipine\"]], \"start\": [[192]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[180]], \"entity_id\": [\"T13\"]}}, \"Severity\": {\"text\": [[\"acute life-threatening\"]], \"start\": [[70]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
12111771_1 | A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"A 73-year-old woman\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"73-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"fever and cough\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL)\"]], \"start\": [[51]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"chronic lymphocytic leukemia (CLL)\"]], \"start\": [[111]], \"entity_id\": [\"T8\"]}, \"Time_elapsed\": {\"text\": [[\"2 weeks\"]], \"start\": [[51]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"fludarabine\"]], \"start\": [[95]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |